Microdissection of clinical AITL samples has identified that IDH2R172 mutations are unique to PD1+ cells [67] and correspondingly, IDH2R172-specific antibody reacts specifically with ICOS+ cells [86]. Here, ICOS is linked to angioimmunoblastic T-cell lymphoma.